Level Biotechnology Inc. (TPEX:3118)
Taiwan · Delayed Price · Currency is TWD 31.75
+0.45 (1.44%)
Aug 26, 2026, 11:52 AM CST
Level Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 709.37 | 736.59 | 731.35 | 660.61 | 593.01 | 677.28 | |
Revenue Growth | -3.54% | 0.72% | 10.71% | 11.40% | -12.44% | 0.71% |
Cost of Revenue | 452.23 | 478.9 | 494.22 | 441.07 | 390.42 | 444.78 |
Gross Profit | 257.14 | 257.7 | 237.13 | 219.55 | 202.59 | 232.5 |
Selling, General & Admin | 158.49 | 160.48 | 148.92 | 137.98 | 123.66 | 138.52 |
Research & Development | 13.23 | 13.7 | 12.95 | 13.77 | 14.03 | 15.02 |
Operating Expenses | 171.73 | 174.15 | 161.81 | 151.99 | 137.69 | 153.54 |
Operating Income | 85.41 | 83.55 | 75.32 | 67.55 | 64.9 | 78.96 |
Interest Expense | -0.17 | -0.2 | -0.28 | -0.33 | -0.35 | -0.38 |
Interest & Investment Income | 3.12 | 3.42 | 5.45 | 5.18 | 2.47 | 1.67 |
Currency Exchange Gain (Loss) | -2.1 | 0.06 | -1.2 | 0.01 | -1.17 | 1.65 |
Other Non Operating Income (Expenses) | 2.18 | 2.53 | 1.82 | 6.14 | 7.21 | 3.12 |
EBT Excluding Unusual Items | 88.44 | 89.36 | 81.1 | 78.55 | 73.07 | 85.02 |
Gain (Loss) on Sale of Investments | 5.31 | 8.22 | - | - | - | - |
Gain (Loss) on Sale of Assets | 0.05 | -0 | 0.02 | 0.1 | 0.08 | -0.13 |
Pretax Income | 93.8 | 97.58 | 81.13 | 78.65 | 73.16 | 84.89 |
Income Tax Expense | 17.78 | 17.88 | 16.31 | 15.75 | 14.69 | 16.71 |
Net Income | 76.02 | 79.7 | 64.81 | 62.91 | 58.47 | 68.18 |
Net Income to Common | 76.02 | 79.7 | 64.81 | 62.91 | 58.47 | 68.18 |
Net Income Growth | 10.34% | 22.97% | 3.03% | 7.59% | -14.25% | 17.46% |
Shares Outstanding (Basic) | 32 | 32 | 32 | 32 | 32 | 32 |
Shares Outstanding (Diluted) | 33 | 33 | 33 | 33 | 33 | 33 |
Shares Change | 0.07% | 0.07% | -0.02% | -0.04% | 0.01% | 0.19% |
EPS (Basic) | 2.34 | 2.46 | 2.00 | 1.94 | 1.80 | 2.10 |
EPS (Diluted) | 2.33 | 2.44 | 1.99 | 1.93 | 1.79 | 2.09 |
EPS Growth | 9.93% | 22.61% | 3.11% | 7.82% | -14.35% | 17.42% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 88.6 | 26.94 | -159.58 | 62.54 | 58.33 | 146.8 |
Free Cash Flow Per Share | 2.71 | 0.82 | -4.89 | 1.92 | 1.79 | 4.49 |
Dividend Per Share | 2.200 | 2.200 | 1.800 | 1.700 | 1.700 | 1.900 |
Dividend Growth | 22.22% | 22.22% | 5.88% | 0% | -10.53% | 18.75% |
Gross Margin | 36.25% | 34.98% | 32.42% | 33.23% | 34.16% | 34.33% |
Operating Margin | 12.04% | 11.34% | 10.30% | 10.23% | 10.95% | 11.66% |
Profit Margin | 10.72% | 10.82% | 8.86% | 9.52% | 9.86% | 10.07% |
Free Cash Flow Margin | 12.49% | 3.66% | -21.82% | 9.47% | 9.84% | 21.67% |
EBITDA | 102.77 | 100.43 | 91.02 | 83.21 | 80.73 | 95.15 |
EBITDA Margin | 14.49% | 13.63% | 12.45% | 12.60% | 13.61% | 14.05% |
D&A For EBITDA | 17.36 | 16.88 | 15.7 | 15.65 | 15.82 | 16.19 |
EBIT | 85.41 | 83.55 | 75.32 | 67.55 | 64.9 | 78.96 |
EBIT Margin | 12.04% | 11.34% | 10.30% | 10.23% | 10.95% | 11.66% |
Effective Tax Rate | 18.96% | 18.32% | 20.11% | 20.02% | 20.08% | 19.69% |